Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Sherry

Showing results (221-230 of 252) with videos related to

Pageof 26
Sort By:
Journal of Pharmaceutical Sciences|April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasetsPatrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2011
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapySteven A Rosenberg, James C Yang, Richard M Sherry, et al.
Molecular Neurobiology|November 24, 2017
Homozygous Expression of Mutant ELOVL4 Leads to Seizures and Death in a Novel Animal Model of Very Long-Chain Fatty Acid DeficiencyBlake R Hopiavuori, Ferenc Deák, Joseph L Wilkerson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2019
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With GlioblastomaStephanie L Goff, Richard A Morgan, James C Yang, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearanceBarbara J Ring, Jenny Y Chien, Kimberly K Adkison, et al.
Journal of Pharmaceutical Sciences|April 1, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distributionRhys Do Jones, Hannah M Jones, Malcolm Rowland, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaMark E Dudley, John R Wunderlich, James C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4Peter Attia, Giao Q Phan, Ajay V Maker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanomaSteven A Rosenberg, Richard M Sherry, Kathleen E Morton, et al.
Pageof 26

Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
Journal of Pharmaceutical Sciences|April 28, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasetsPatrick Poulin, Hannah M Jones, Rhys Do Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2011
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapySteven A Rosenberg, James C Yang, Richard M Sherry, et al.
Molecular Neurobiology|November 24, 2017
Homozygous Expression of Mutant ELOVL4 Leads to Seizures and Death in a Novel Animal Model of Very Long-Chain Fatty Acid DeficiencyBlake R Hopiavuori, Ferenc Deák, Joseph L Wilkerson, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2019
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With GlioblastomaStephanie L Goff, Richard A Morgan, James C Yang, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approachPatrick Poulin, Rhys D O Jones, Hannah M Jones, et al.
Journal of Pharmaceutical Sciences|May 5, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearanceBarbara J Ring, Jenny Y Chien, Kimberly K Adkison, et al.
Journal of Pharmaceutical Sciences|April 1, 2011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distributionRhys Do Jones, Hannah M Jones, Malcolm Rowland, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 10, 2002
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanomaMark E Dudley, John R Wunderlich, James C Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4Peter Attia, Giao Q Phan, Ajay V Maker, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanomaSteven A Rosenberg, Richard M Sherry, Kathleen E Morton, et al.
Pageof 26